47 studies found for:    Open Studies | "Cytomegalovirus Infections"
Show Display Options
Rank Status Study
21 Recruiting An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls
Condition: Cytomegalovirus Infections, Transplantation
Intervention:
22 Recruiting Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Condition: Cytomegalovirus Congenital Infection
Intervention: Biological: standard intravenous immunoglobulin
23 Unknown  Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
Condition: Cytomegalovirus Infection
Interventions: Biological: Adoptive Cellular Therapy;   Drug: Best available antiviral drug therapy
24 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo
25 Recruiting Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Conditions: Sensorineural Hearing Loss;   Cytomegalovirus Infection
Intervention:
26 Recruiting Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus
Conditions: Cytomegalovirus Infection;   Healthy, no Evidence of Disease
Interventions: Biological: multi-CMV epitope modified vaccinia Ankara vaccine;   Other: laboratory biomarker analysis
27 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
28 Recruiting Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero
Condition: Congenital Cytomegalovirus Infection
Intervention: Other: Standardized test report
29 Not yet recruiting Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss
Conditions: Congenital Cytomegalovirus;   Hearing Loss
Interventions: Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution;   Drug: Placebo
30 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
31 Recruiting CMV Modulation of the Immune System in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis;   CMV Infection
Intervention: Drug: Valaciclovir
32 Recruiting TT-CMV Observational Birth Cohort Study
Condition: Cytomegalovirus Disease
Intervention:
33 Recruiting Study to Explore CMV Infection in Adolescent Girls
Condition: Infections, Cytomegalovirus
Interventions: Procedure: Blood collection;   Procedure: Urine collection;   Procedure: Dry urine collection;   Procedure: Saliva collection;   Procedure: Urine and/ or saliva collection from newborn in case of pregnancy
34 Recruiting Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients
Condition: Kidney Transplantation Recipients
Intervention:
35 Recruiting Evaluate Cytomegalovirus (CMV)-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients With CMV-positive Serology (R+) Prior to Transplant and Its Involvement in the Development of CMV Infection
Condition: Cytomegalovirus
Intervention:
36 Recruiting Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)
Condition: Bone Marrow Transplantation
Intervention:
37 Recruiting Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
Conditions: Renal Transplant Recipient;   Immunized Against the Cytomegalovirus.
Intervention: Biological: CMV Infection
38 Recruiting Primary Transplant or Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Condition: Cytomegalovirus
Intervention: Genetic: CMV-pp65 CTLs
39 Unknown  T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
Conditions: Graft Versus Host Disease;   Nonneoplastic Condition
Interventions: Biological: adoptive immunotherapy;   Biological: alemtuzumab;   Biological: in vitro-treated peripheral blood lymphocyte therapy;   Drug: foscarnet sodium;   Drug: ganciclovir;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: infection prophylaxis and management;   Procedure: peripheral blood stem cell transplantation;   Procedure: standard follow-up care;   Radiation: radiation therapy
40 Unknown  Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
Condition: Cytomegalovirus
Interventions: Drug: ganciclovir treatment or monitoring of viral load.;   Other: Monitor or treat with ganciclovir

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-47) Show next page of results
Indicates status has not been verified in more than two years